Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis

Int J Tuberc Lung Dis. 2012 Feb;16(2):203-5. doi: 10.5588/ijtld.11.0445.


Following the World Health Organization's endorsement of the Xpert® MTB/RIF assay, which rapidly and simultaneously diagnoses tuberculosis (TB) and detects resistance to rifampin (RMP), the question arises to what extent RMP resistance is an adequate marker for multidrug-resistant TB (MDR-TB). A retrospective analysis of data from >81 countries and subnational settings demonstrated that >40% of RMP-resistant isolates from new TB cases did not display resistance to isoniazid (INH) in settings with relatively low MDR-TB prevalence (one third of all countries and subnational settings). Results indicated the need for INH susceptibility testing in addition to RMP susceptibility testing.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Global Health
  • Humans
  • Incidence
  • Isoniazid / therapeutic use*
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Prevalence
  • Retrospective Studies
  • Rifampin / therapeutic use*
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / epidemiology*


  • Antitubercular Agents
  • Isoniazid
  • Rifampin